Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

Core Insights - Kodiak Sciences Inc. is focused on developing transformative therapeutics for retinal diseases and will present at several upcoming investor conferences [1][2][7] - The company is advancing a clinical pipeline that includes three product candidates, with two in late-stage development [3][4][5][6] Company Overview - Kodiak Sciences is a biopharmaceutical company dedicated to treating retinal diseases using its proprietary ABC Platform™, which integrates protein-based and chemistry-based therapies [3] - The company aims to address leading causes of blindness globally through innovative drug design and development [3] Clinical Pipeline - Kodiak's lead product, tarcocimab, is an anti-VEGF antibody biopolymer conjugate targeting diabetic retinopathy and wet age-related macular degeneration [4] - KSI-501, a bispecific antibody biopolymer conjugate, is designed to treat retinal vascular diseases by inhibiting IL-6 and VEGF pathways, with Phase 3 studies expected to begin mid-2024 [5] - KSI-101, an unconjugated protein candidate, is being developed for retinal inflammatory diseases, filling a gap in current treatment options [6] Upcoming Events - Kodiak will participate in the Clinical Trials at the Summit 2024 on June 8, where presentations on its clinical pipeline will be made [2] - The company will also present at the Jefferies Healthcare Conference on June 6 and the Goldman Sachs Global Healthcare Conference on June 13 [7][8]